Forty Seven CEO and leadership

Dr. McCamish has significant leadership in the life science industry, most recently serving as President and Chief Executive Officer of Forty Seven Inc., which he led through IPO and multiple financings until the acquisition by Gilead for approximately $4.9 Billion. Dr. McCamish has also served as the Global Head of Biopharmaceutical Development of Novartis' Sandoz division, receiving Novartis's Chairman award each year from 2010-2015. Prior to his time at Novartis, Dr. McCamish was a Vice President and Chief Medical Officer at several companies including PDL BioPharma, Perlegen Sciences, and Facet Labs, which was acquired by Abbott Laboratories due in part to Dr. McCamish's work advancing multiple myeloma and multiple sclerosis therapies. Additionally, Dr. McCamish has also held senior research and development roles at Amgen Inc. and Abbott Laboratories.

Dr. McCamish received his PhD in Human Nutrition from Penn State University and his MD from the University of California, Los Angeles (UCLA). He completed his residency and fellowship training at the University of California, Davis (UC Davis). Dr. McCamish has been named one of the top 50 global antibody industry influencers by the European Antibody Congress and has held professorships at UC Davis and The Ohio State University.

Norm has more than 20 years of experience as a patent attorney in the biotechnology industry. Prior to joining Forty Seven, he was Vice President of Intellectual Property and Chief Patent Counsel at Verinata Health, and, after Verinata’s acquisition by Illumina, was a Senior Director of Intellectual Property at Illumina. Prior to that, Norm was Vice President of Intellectual Property and Chief Patent Counsel at Maxygen. During his 11 years at Maxygen, he developed, defended and enforced an industry-leading patent portfolio in directed molecular evolution (ranked #1 in the MIT Technology Review Patent Scorecard in 2003 for biotechnology patent estates). This patent portfolio also formed the basis for several successful companies spun out or sold by Maxygen including, Codexis (IPO in 2010), Verdia (acquired by DuPont) and Avidia (acquired by Amgen). Prior to Maxygen, Norm was a patent attorney at Chiron Corporation where he was responsible for Chiron’s gene therapy patent portfolio. He began his legal career as an attorney at Townsend and Townsend and Crew, working on biotechnology patent prosecution and strategy. He holds a Ph.D. in Biochemistry from the University of Washington, a J.D. from Golden Gate University School of Law in San Francisco, and received a B.S. in Biochemistry from the University of California, Davis.

Dr. McCamish has significant leadership in the life science industry, most recently serving as President and Chief Executive Officer of Forty Seven Inc., which he led through IPO and multiple financings until the acquisition by Gilead for approximately $4.9 Billion. Dr. McCamish has also served as the Global Head of Biopharmaceutical Development of Novartis' Sandoz division, receiving Novartis's Chairman award each year from 2010-2015. Prior to his time at Novartis, Dr. McCamish was a Vice President and Chief Medical Officer at several companies including PDL BioPharma, Perlegen Sciences, and Facet Labs, which was acquired by Abbott Laboratories due in part to Dr. McCamish's work advancing multiple myeloma and multiple sclerosis therapies. Additionally, Dr. McCamish has also held senior research and development roles at Amgen Inc. and Abbott Laboratories.

Dr. McCamish received his PhD in Human Nutrition from Penn State University and his MD from the University of California, Los Angeles (UCLA). He completed his residency and fellowship training at the University of California, Davis (UC Davis). Dr. McCamish has been named one of the top 50 global antibody industry influencers by the European Antibody Congress and has held professorships at UC Davis and The Ohio State University.